{"entity":{"id":"slamf7","kind":"target","name":"SLAMF7 (CS1)","aka":[],"tldr":"A surface protein found on myeloma cells and on natural killer cells. Elotuzumab tags myeloma cells with it while also switching on the natural killer cells that carry it.","summary":"SLAMF7, also known as CS1 or CD319, is a signalling lymphocyte activation molecule family receptor expressed at high levels on malignant plasma cells and on natural killer cells, with little expression on other normal tissues. Elotuzumab, a humanised antibody against SLAMF7, marks myeloma cells for antibody-dependent cellular cytotoxicity and directly activates natural killer cells through the same receptor. It has no single-agent activity but improves outcomes with lenalidomide or pomalidomide plus dexamethasone, the basis of its 2015 and 2018 approvals.","asOf":"2026-09-04","wikipedia":"https://en.wikipedia.org/wiki/SLAMF7","links":[{"label":"UniProt Q9NQ25: SLAMF7","url":"https://www.uniprot.org/uniprotkb/Q9NQ25/entry"}],"tags":[],"related":[],"cancers":["multiple-myeloma"],"sections":[],"technologies":[],"targets":[],"drugs":["elotuzumab"],"companies":[],"institutions":[],"pathways":[],"terms":["adcc"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"symbol":"SLAMF7","role":[],"sources":[],"specificity":"tumour-associated","distribution":"one-type","specificityNote":"Tumour-associated overexpression: 1 antibody (Elotuzumab) aim at the antigen, which HPA finds stained high in 2 normal tissues; the medicine relies on the tumour carrying more of it than the normal tissue it shares it with. HPA SLAMF7: RNA tissue enhanced (intestine 31 nTPM, lymphoid tissue 58 nTPM, stomach 1 32 nTPM); high antibody staining in 2 normal tissues. Distribution: 1 cancer family in the corpus carries a prevalence row, label threshold or catalogue link for it (Multiple myeloma); Open Targets associates it with 1 specific cancer type at or above 0.5 (plasma cell myeloma). (Rule 5 of scripts/fetch-target-specificity.ts.)","specificitySources":[{"label":"Human Protein Atlas SLAMF7 tissue","url":"https://www.proteinatlas.org/ENSG00000026751-SLAMF7/tissue","note":"RNA tissue and blood lineage specificity, normal tissue antibody staining (version 25.1, CC BY-SA 3.0)"},{"label":"Human Protein Atlas SLAMF7 pathology","url":"https://www.proteinatlas.org/ENSG00000026751-SLAMF7/pathology","note":"patients per staining level per cancer type (version 25.1, CC BY-SA 3.0)"},{"label":"Open Targets ENSG00000026751 associations","url":"https://platform.opentargets.org/target/ENSG00000026751/associations","note":"cancer associations at or above 0.5 (CC0)"}],"hgnc":"HGNC:21394","ensembl":"ENSG00000026751","uniprot":"Q9NQ25","entrez":"57823","firstDescribed":1999,"firstDescribedBasis":"sequence","firstDescribedNote":"Earliest sequence paper UniProt cites for the protein: Fujii et al, 1999, \"Homo sapiens mRNA for FOAP-12 protein, complete cds\".","firstDescribedSource":"https://www.uniprot.org/uniprotkb/Q9NQ25/entry","biology":"SLAM family receptor signalling through EAT-2 in natural killer cells; highly expressed on plasma cells and myeloma cells.","whereFound":["Multiple myeloma (near-universal expression on malignant plasma cells)"],"targetClass":"surface-antigen","prevalence":[{"cancerId":"multiple-myeloma","pct":"over 95","measure":"CS1 (SLAMF7) expression on myeloma cells","source":"https://doi.org/10.1158/1078-0432.CCR-07-4246"}]},"route":"/targets/slamf7/","neighbours":{"cancer":[{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"}],"drug":[{"id":"elotuzumab","kind":"drug","name":"Elotuzumab","route":"/drugs/elotuzumab/"}],"term":[{"id":"adcc","kind":"term","name":"ADCC (antibody-dependent cellular cytotoxicity)","route":"/terms/adcc/"}]}}